A  1  Characteristics of the pathogen?  Laboratory study  Van der Worp [37]^{3}

A  2  Subtypes, serotypes and local epidemiology of the pathogen?  Laboratory study  Van der Worp [37] 
   Crosssectional study  AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47] 
A  3  Modes of transmission?  Animal study  Van der Worp [37] 
   Cohort study  Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44] 
   Case series  Cho [30] 
   Casecontrol study  Downs [31], SIGN [41], Cho [30], EPHPP [38], NOS [44] 
B  4  Incidence of the disease?  Cohort study  Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44] 
B  5  Prevalence/seroprevalence of the disease?  Crosssectional study  AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47] 
B  6  Consequences or sequelae of the disease (hospitalization/mortality/complications/disabilities)?  Cohort study  Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44] 
Case series  Cho [30] 
Case report  Cho [30] 
B  7  Perception of the disease in the target population?  Crosssectional study  AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47] 
   Cohort study  Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44] 
   Focus groups  NICE [48], CASP [36] 
   Interview study  
C  8  Sensitivity of tests?  Diagnostic test accuracy study  SIGN [42] 
C  9  Specificity of tests?  Diagnostic test accuracy study  SIGN [42] 
D  10  Risk factors (for transmission/colonization/infection/disease/exacerbation/complication)?  Cohort study  Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44] 
Casecontrol study  Downs [31], SIGN [41], Cho [30], EPHPP [38], NOS [44] 
Ecological study  NICE [47] 
Crosssectional study  AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47] 
   Animal study  Van der Worp [37] 
E  11  Effects of intervention (in terms of efficacy/effectiveness/surrogate markers/adverse events/harms)?  Controlled beforeandafter study  Downs [31], NICE [46], EPHPP [38] 
   RCT  Cochrane [35], Downs [31], SIGN [39], NICE [46], EPHPP [38] 
   NRCT  Downs [31], NICE [46], EPHPP [38] 
   Clusterrandomized trial  Downs [31], NICE [46], EPHPP [38] 
   Cohort study  Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44] 
   Casecontrol study  Downs [31], SIGN [41], Cho [30], EPHPP [38], NOS [44] 
   Uncontrolled beforeandafter study  Downs [31], NICE [46], EPHPP [38] 
   Ecological study  NICE [47] 
   Interrupted time series  EPOC [50], EPHPP [38] 
   Selfcontrolled case series  Cho [30], NOS [44], SIGN [41] 
F  12  Feasible to implement?  Crosssectional study  AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47] 
   Cohort study  Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44] 
   Focus groups  NICE [48], CASP [36] 
   Interview study  
F  13  Costeffectiveness of the intervention?  Costeffectiveness (benefit, consequence) analysis  SIGN [43], NICE [49], QHES [34] 
   Costutility analysis  QHES [34] 
F  14  Acceptable to stakeholders?  Focus groups  NICE [48], CASP [36] 
   Interview study  
   Crosssectional study  AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47] 
F  15  Equitable?  Crosssectional study  AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47] 
   Cohort study  Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44] 
F  16  Enablers/barriers to success?  Crosssectional study  AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47] 
   Interview study (observation)  NICE [48], CASP [36] 
   Document analysis  
   Focus groups  
   Process evaluation  
F  17  Coverage rates for positive population level effects?  Cohort study  Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44] 
   Noneconomic modeling study  SIGN [43], NICE [49] 
F  18  Communication of advice?  RCT  Cochrane [35], Downs [31], SIGN [39], NICE [46], EPHPP [38] 
   NRCT  Downs [31], NICE [46], EPHPP [38] 
   Cohort study  Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44] 
   Crosssectional study  AlJader [33], Loney [32], Hoy [45], Cho [30], NICE [47] 
   Focus groups  NICE [48], CASP [36] 
   Interview study  
F  19  Weighing and valuing of population preferences?  Crosssectional study  AlJader [33], Loney [32], Hoy [5], Cho [30], NICE [47] 
   Focus groups  NICE [48], CASP [36] 
   Interview study  
F  20  Effectiveness of alternative measures?  Controlled beforeafter study  Downs [31], NICE [46], EPHPP [38] 
   RCT  Cochrane [35], Downs [31], SIGN [39], NICE [46], EPHPP [38] 
   NRCT  Downs [31], NICE [46], EPHPP [38] 
   Clusterrandomized trial  Downs [31], NICE [46], EPHPP [38] 
   Cohort study  Downs [31], SIGN [40], Cho [30], EPHPP [38], NOS [44] 
   Casecontrol study  Downs [31], SIGN [41], Cho [30], EPHPP [38], NOS [44] 
   Uncontrolled beforeafter study  Downs [31], NICE [46], EPHPP [38] 
   Ecological study  NICE [47] 
   Interrupted time series  EPOC [50], EPHPP [38] 
   Selfcontrolled case series  Cho [30], NOS [44], SIGN [41] 